tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Pericarditis D010493 6 associated lipids
Blindness D001766 6 associated lipids
Alopecia Areata D000506 6 associated lipids
Gliosis D005911 6 associated lipids
Bronchiolitis D001988 6 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Chronic Disease D002908 7 associated lipids
Metaplasia D008679 7 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Dyslipidemias D050171 7 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Behcet Syndrome D001528 7 associated lipids
Hepatitis C D006526 7 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Dementia, Vascular D015140 7 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Facial Dermatoses D005148 7 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Tachycardia D013610 7 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Folliculitis D005499 7 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Lupus Nephritis D008181 8 associated lipids
Thyroid Diseases D013959 8 associated lipids
Fistula D005402 8 associated lipids
Renal Insufficiency D051437 8 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Opportunistic Infections D009894 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Sinusitis D012852 9 associated lipids
Leukocytosis D007964 9 associated lipids
Cicatrix D002921 9 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Urination Disorders D014555 9 associated lipids
Hypertension, Renal D006977 9 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Cacciarelli TV et al. An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1999 Transplantation pmid:10507484
Whalen HR et al. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime. 2017 Transplantation pmid:26950724
Shirakata Y et al. Inhibitory effect of plasma FKBP12 on immunosuppressive activity of FK506. 1995 Transplantation pmid:8545894
Burke GW et al. Advances in pancreas transplantation. 2004 Transplantation pmid:15201688
Moffatt SD et al. Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. 1999 Transplantation pmid:10342309
Yoshihara S et al. Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone human leukocyte antigen-haploidentical nonmyeloablative stem cell transplantation. 2004 Transplantation pmid:15077022
Briggs D et al. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients. 2003 Transplantation pmid:12829912
Ueno P et al. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus. 2017 Transplantation pmid:27490418
Bierer BE et al. Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. 1990 Transplantation pmid:1694317
Chaftari AM et al. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. 2012 Transplantation pmid:22814329
Utsugi R et al. Induction of transplantation tolerance with a short course of tacrolimus (FK506): I. Rapid and stable tolerance to two-haplotype fully mhc-mismatched kidney allografts in miniature swine. 2001 Transplantation pmid:11391221
Yin DP et al. Lewis rat pancreas, but not cardiac xenografts, are resistant to anti-gal antibody mediated hyperacute rejection. 2001 Transplantation pmid:11391223
Krentz AJ Posttransplantation Diabetes Mellitus in FK-506-Treated Renal Transplant Recipients: Analysis of Incidence and Risk Factors. Transplantation 2001; 72: 1655. 2001 Transplantation pmid:11726815
Bruce DS et al. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. 2001 Transplantation pmid:11726823
Shao X et al. Tacrolimus-associated ischemic optic neuropathy and posterior reversible encephalopathy syndrome after small bowel transplantation. 2012 Transplantation pmid:23128973
Nicolai S and Bunyavanich S Hypersensitivity reaction to intravenous but not oral tacrolimus. 2012 Transplantation pmid:23128975
Barth RN et al. Prolonged survival of composite facial allografts in non-human primates associated with posttransplant lymphoproliferative disorder. 2009 Transplantation pmid:19996923
Kaplan B et al. Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. 1996 Transplantation pmid:8900321
Bronster DJ et al. Tacrolimus-associated mutism after orthotopic liver transplantation. 2000 Transplantation pmid:11014653
Newell KA et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. 1996 Transplantation pmid:8779685
Lufft V et al. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. 1996 Transplantation pmid:8779695
Coto E and Tavira B Pharmacogenetics of calcineurin inhibitors in renal transplantation. 2009 Transplantation pmid:19667964
Kadry Z et al. Kaposi's sarcoma in liver transplant recipients on FK506. 1998 Transplantation pmid:9583882
Hooper DK et al. Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. 2012 Transplantation pmid:22491658
Sarwal MM et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. 2003 Transplantation pmid:14627912
Ciancio G et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. 2008 Transplantation pmid:18622280
Bolin P et al. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results. 2008 Transplantation pmid:18622283
Richards KR et al. Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients. 2014 Transplantation pmid:24784360
Chung BH et al. Suppressive Effect of 1α,25-Dihydroxyvitamin D3 on Th17-Immune Responses in Kidney Transplant Recipients With Tacrolimus-Based Immunosuppression. 2017 Transplantation pmid:28107277
Klupp J et al. Indications of mycophenolate mofetil in liver transplantation. 2005 Transplantation pmid:16286893
Yang H et al. Liposomal encapsulation significantly enchances the immunosuppressive effect of tacrolimus in a discordant islet xenotransplant model. 2002 Transplantation pmid:11907415
St A Nunes FA and Lucey MR Searching for a balance when applying immunosuppression after liver transplantation. 2001 Transplantation pmid:11258425
Steinmüller TM et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. 1994 Transplantation pmid:7524203
Marin-Casino M et al. Significant tacrolimus and dronedarone interaction in a kidney transplant recipient. 2014 Transplantation pmid:25243519
Sonoda T et al. Outcome of 3 years of immunosuppression with tacrolimus in more than 1,000 renal transplant recipients in japan. 2003 Transplantation pmid:12548123
Reich DJ et al. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. 2005 Transplantation pmid:16003228
Hardinger KL et al. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. 2005 Transplantation pmid:16003231
Roberti I et al. Evidence that the systematic analysis of bile cytology permits monitoring of hepatic allograft rejection. 1992 Transplantation pmid:1384182
Guthery SL et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. 2003 Transplantation pmid:12698085
Jain A et al. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. 2003 Transplantation pmid:12698091
Danziger-Isakov LA et al. The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation. 2009 Transplantation pmid:19461492
Guasch A et al. Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. 2010 Transplantation pmid:20811320
Pascual J et al. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. 2004 Transplantation pmid:15599321
Azzola A et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. 2004 Transplantation pmid:14742993
Ferdman RM et al. Rapid intravenous desensitization to antithymocyte globulin in a patient with aplastic anemia. 2004 Transplantation pmid:14743005
Murase N et al. Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. 1993 Transplantation pmid:7678353
Yilmaz MI et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. 2005 Transplantation pmid:16378057
Vítko S et al. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. 2005 Transplantation pmid:16378069
Vacher-Coponat H et al. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation. 2012 Transplantation pmid:22228415
Guitard J et al. Predictive factors for anemia six and twelve months after orthotopic liver transplantation. 2006 Transplantation pmid:16770241